Lactobacillus casei DG (Enterolactis duo®) ( DrugBank: Lactobacillus casei )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
6. Parkinson disease
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04293159 (ClinicalTrials.gov) | May 14, 2019 | 19/2/2020 | Effect of Probiotic on Constipation in Patients With Parkinson's Disease | Effect of Probiotic on Constipation and on Neuropsychological Performance in Patients With Parkinson's Disease | Parkinson Disease;Constipation | Dietary Supplement: Lactobacillus casei DG (Enterolactis duo®) | University of Salerno | Roberto Erro;Maria Teresa Pellecchia;Antonella Santonicola;Carolina Ciacci | Recruiting | 18 Years | 75 Years | All | 30 | N/A | Italy |